UA97975C2 - Substituted phenoxy n-alkylated thiazoledinediones as estrogen related receptor-alpha modulators - Google Patents
Substituted phenoxy n-alkylated thiazoledinediones as estrogen related receptor-alpha modulatorsInfo
- Publication number
- UA97975C2 UA97975C2 UAA200910121A UAA200910121A UA97975C2 UA 97975 C2 UA97975 C2 UA 97975C2 UA A200910121 A UAA200910121 A UA A200910121A UA A200910121 A UAA200910121 A UA A200910121A UA 97975 C2 UA97975 C2 UA 97975C2
- Authority
- UA
- Ukraine
- Prior art keywords
- arthritis
- disease
- cartilage
- chronic
- injury
- Prior art date
Links
- 102100036832 Steroid hormone receptor ERR1 Human genes 0.000 title 1
- 108091008559 estrogen-related receptor alpha Proteins 0.000 title 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 206010003246 arthritis Diseases 0.000 abstract 2
- 210000000988 bone and bone Anatomy 0.000 abstract 2
- 210000000845 cartilage Anatomy 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000002574 reactive arthritis Diseases 0.000 abstract 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 abstract 1
- 206010003267 Arthritis reactive Diseases 0.000 abstract 1
- 208000025940 Back injury Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010006458 Bronchitis chronic Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010007710 Cartilage injury Diseases 0.000 abstract 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 abstract 1
- 208000005243 Chondrosarcoma Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000012514 Cumulative Trauma disease Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 208000004575 Infectious Arthritis Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000010191 Osteitis Deformans Diseases 0.000 abstract 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000027868 Paget disease Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 abstract 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 abstract 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 abstract 1
- 208000033464 Reiter syndrome Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 229940046836 anti-estrogen Drugs 0.000 abstract 1
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 230000022159 cartilage development Effects 0.000 abstract 1
- 208000002849 chondrocalcinosis Diseases 0.000 abstract 1
- 208000017568 chondrodysplasia Diseases 0.000 abstract 1
- 208000007451 chronic bronchitis Diseases 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000019439 energy homeostasis Effects 0.000 abstract 1
- 239000000328 estrogen antagonist Substances 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 208000027202 mammary Paget disease Diseases 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000011164 ossification Effects 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 230000000010 osteolytic effect Effects 0.000 abstract 1
- 208000005368 osteomalacia Diseases 0.000 abstract 1
- 208000028169 periodontal disease Diseases 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000001223 septic arthritis Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance., (I)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98345807P | 2007-03-07 | 2007-03-07 | |
| PCT/US2008/056018 WO2008109731A2 (en) | 2007-03-07 | 2008-03-06 | Substituted phenoxy n-alkylated thiazoledinedione as estrogen related receptor-alpha modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA97975C2 true UA97975C2 (en) | 2012-04-10 |
Family
ID=52293819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200910121A UA97975C2 (en) | 2007-03-07 | 2008-03-06 | Substituted phenoxy n-alkylated thiazoledinediones as estrogen related receptor-alpha modulators |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA97975C2 (en) |
-
2008
- 2008-03-06 UA UAA200910121A patent/UA97975C2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009009519A (en) | Substituted phenoxy n-alkylated thiazoledinedione as estrogen related receptor-alpha modulators. | |
| MX2009009520A (en) | Substituted phenoxy aminothiazolones as estrogen related receptor-alpha modulators. | |
| MX2009009517A (en) | Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators. | |
| MX2012009529A (en) | Aminothiazolones as estrogen related receptor-alpha modulators. | |
| MX2012009528A (en) | Aminothiazolones as estrogen related receptor-alpha modulators. | |
| JP2010520307A5 (en) | ||
| JP2010520306A5 (en) | ||
| JP2012506473A5 (en) | ||
| US20150224034A1 (en) | Dental materials and method of manufacture | |
| US20190031689A1 (en) | Alpha-silane coupling agent and application thereof | |
| CA2715113A1 (en) | 11 beta-hydroxysteroid dehydrogenase inhibitors | |
| UA97975C2 (en) | Substituted phenoxy n-alkylated thiazoledinediones as estrogen related receptor-alpha modulators | |
| JP2009545549A5 (en) | ||
| JP4987845B2 (en) | Method for producing chloroprene rubber composition, chloroprene rubber composition, and adhesive using the same | |
| WO2010007363A3 (en) | Preparation of fluorine-labelled compounds | |
| MY160230A (en) | Thermoplastic stiffening materials | |
| JP2012233153A5 (en) | ||
| US7803850B2 (en) | Camphorquinone derivative having acylphosphine oxide group, photopolymerization initiator and photo/chemical polymerization initiator containing the same and hardenable composition containing the same | |
| CN110016124A (en) | A kind of A- π-D- π-A type sensitizer based on diphenyl sulphone (DPS) and preparation method thereof, application | |
| Hangeland et al. | A new class of high affinity thyromimetics containing a phenyl-naphthylene core | |
| JP2022056984A (en) | Method for synthesizing and manufacturing a low polymerization shrinkable monomer for medical and dental use using a radically polymerizable monomer as a solvent | |
| CN111072539A (en) | A kind of simple preparation method of methyl thiomethanesulfonate | |
| JP5753717B2 (en) | Method for producing aromatic sulfide compound | |
| JP2016023176A (en) | Compound and production method thereof | |
| CN107011212A (en) | A kind of preparation method of the secondary monooctyl ester of cyanoacetic acid |